Microbial Enzymatic Drug Modification to Improve Treatment Outcomes

微生物酶药物修饰以改善治疗效果

• 批准号: 131613
• 金额: $ 16.25万
• 依托单位: HYPHA DISCOVERY LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131613
• 关键词: Microbial; Enzymatic; Drug; Modification; Improve

The major healthcare imperatives are to deliver effective prevention and treatment of diseases. Whist pharmaceutical intervention of disease progress is effective in many cases, the use of medicines can also lead to adverse reactions resulting in the need for further medical intervention, compounding the cost of therapy. The aim of this project is to further develop a platform product, already used in part by the pharmaceutical industry, to allow the greater exploration of the chemical space of a potential drug to overcome the main cause of adverse reactions, polymorphic variation of cytochrome P450 enzymes (CYPs). Hypha currently uses microbial biotransformations to produce metabolites and effect lead molecule-diversification for Pharma-based clients. The feasibility of a cell-free version of the product will be assessed to target advantages comprising speed of delivery and use in a kit form, enabling Pharma clients to innovatively deliver improved medicines with more predictable properties.

医疗保健的主要任务是提供有效的疾病预防和治疗。虽然药物干预疾病进展在许多情况下是有效的，但药物的使用也可能导致不良反应，导致需要进一步的医疗干预，增加治疗费用。该项目的目的是进一步开发一种平台产品，该产品已部分被制药行业使用，以更好地探索潜在药物的化学空间，以克服不良反应的主要原因，即细胞色素P450酶（CYP）的多态性变异。Hypha目前使用微生物生物转化来生产代谢物，并为制药客户实现铅分子多样化。该产品的无细胞版本的可行性将被评估，以目标优势，包括交付速度和以试剂盒形式使用，使制药客户能够创新地提供具有更可预测特性的改进药物。